References
7 Kidd PM. Autism, an extreme challenge to integrative medicine. Part: 1: The knowledge base. Altern
Med Rev. 2002 Aug;7(4):292-316; Kidd PM. Autism, an extreme challenge to integrative medicine.
Part 2: medical management. Altern Med Rev. 2002 Dec;7(6):472-99
8 Kidd PM. An approach to the nutritional management of autism. Altern Ther Health Med. 2003 Sep-Oct;9(5):22-31
9 Curtis LT, Patel K. Nutritional and environmental approaches to preventing and treating autism and
attention deficit hyperactivity disorder (ADHD): a review. J Altern Complement Med. 2008 Jan-Feb;14
(1):79-85; Moretti P, Sahoo T, Hyland K, Bottiglieri T, Peters S, del Gaudio D, Roa B, Curry S, Zhu H,
Finnell RH, Neul JL, Ramaekers VT, Blau N, Bacino CA, Miller G, Scaglia F. Cerebral folate deficiency with developmental delay, autism, and response to folinic acid. Neurology. 2005 Mar 22;64(6):1088-90
10 Monks G, Juracek L, Weigand D, Magro C, Cornelison R, Crowson AN. A case of scurvy in an autistic boy. J Drugs Dermatol. 2002 Jul;1(1):67-9; Steinemann TL, Christiansen SP. Vitamin A deficiency and xerophthalmia in an autistic child. Arch Ophthalmol. 1998 Mar;116(3):392-3; Clark JH, Rhoden DK, Turner DS. Symptomatic vitamin A and D deficiencies in an eight-year-old with autism. JPEN J Parenter Enteral Nutr. 1993 May-Jun;17(3):284-6; Stewart C, Latif A. Symptomatic nutritional rickets in a teenager with autistic spectrum disorder. Child Care Health Dev. 2008 Mar;34(2):276-8
11 McGinnis WR. Oxidative stress in autism. Altern Ther Health Med. 2004 Nov-Dec;10(6):22-36
12 Horvath K, Perman JA. Autistic disorder and gastrointestinal disease. Curr Opin Pediatr. 2002 Oct;14
(5):583-7
13 McGinnis WR. Mercury and autistic gut disease. Environ Health Perspect. 2001 Jul;109(7):A303-4
14 Mutter J, Naumann J, Schneider R, Walach H, Haley B. Mercury and autism: accelerating evidence Neuro Endocrinol Lett. 2005 Oct;26(5):439-46
15 Geier DA, Geier MR. A prospective study of mercury toxicity biomarkers in autistic spectrum disorders. J Toxicol Environ Health A. 2007 Oct;70(20):1723-30; Adams JB, Romdalvik J, Ramanujam VM, Legator MS. Mercury, lead, and zinc in baby teeth of children with autism versus controls. J Toxicol Environ Health A. 2007 Jun;70(12):1046-51; Geier DA, Geier MR. A case series of children with apparent mercury toxic encephalopathies manifesting with clinical symptoms of regressive autistic disorders. J Toxicol Environ Health A. 2007 May 15;70(10):837-51; Fido A, Al-Saad S. Toxic trace elements in the hair of children with autism. Autism. 2005 Jul;9(3):290-8; Palmer RF, Blanchard S, Stein Z, Mandell D, Miller C. Environmental mercury release, special education rates, and autism disorder: an ecological study of Texas. Health Place. 2006 Jun;12(2):203-9
16 Patel K, Curtis LT. A comprehensive approach to treating autism and attention-deficit hyperactivity
disorder: a prepilot study. J Altern Complement Med. 2007 Dec;13(10):1091-7
17 Rossignol DA, Rossignol LW. Hyperbaric oxygen therapy may improve symptoms in autistic children. Med Hypotheses. 2006;67(2):216-28
18 Chungpaibulpatana J, Sumpatanarax T, Thadakul N, Chantharatreerat C, Konkaew M, Aroonlimsawas M. Hyperbaric oxygen therapy in Thai autistic children. J Med Assoc Thai. 2008 Aug;91(8):1232-8
19 Rossignol DA, Rossignol LW, James SJ, Melnyk S, Mumper E. The effects of hyperbaric oxygen therapy on oxidative stress, inflammation, and symptoms in children with autism: an open-label pilot study. BMC Pediatr. 2007 Nov 16;7:36
20 Rossignol DA. Hyperbaric oxygen therapy might improve certain pathophysiological findings in
autism. Med Hypotheses. 2007;68(6):1208-27
21 Elchaar GM, Maisch NM, Augusto LM, Wehring HJ. Efficacy and safety of naltrexone use in pediatric patients with autistic disorder. Ann Pharmacother. 2006 Jun;40(6):1086-95; Williams PG, Allard A, Sears L, Dalrymple N, Bloom AS. Brief report: case reports on naltrexone use in children with autism: controlled observations regarding benefits and practical issues of medication management. J Autism Dev Disord. 2001 Feb;31(1):103-8; Willemsen-Swinkels SH, Buitelaar JK, van Berckelaer-Onnes IA, van Engeland H. Brief report: six months continuation treatment in naltrexone-responsive children with autism: an open-label case-control design. J Autism Dev Disord. 1999 Apr;29(2):167-9; Riddle MA, Bernstein GA, Cook EH, Leonard HL, March JS, Swanson JM. Anxiolytics, adrenergic agents, and naltrexone. J Am Acad Child Adolesc Psychiatry. 1999 May; 38(5):546-56